Other languages Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Real-time Estimate Cboe BZX Other stock markets 10:03:49 2024-04-26 am EDT			5-day change	1st Jan Change
0.785 ^USD	+2.68%		+5.76%	-61.81%

Apr. 15	Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	CI
Apr. 02	Top Midday Decliners	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	Apr. 15
Top Midday Decliners	Apr. 02
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	Apr. 02
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	Apr. 01
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	Apr. 01
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	Apr. 01
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial	Feb. 12
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023	23-10-11
Gritstone bio Offers Stock Options to Three New Employees	23-10-10
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	23-09-28
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours	23-09-27
Gritstone Bio, Inc. Receives BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19	23-09-27
Gritstone bio, Genevant Sciences Sign License Agreement for Use of LNP Technology	23-08-15
Gritstone Bio and Genevant Sciences Announce Option and License Agreement	23-08-15
Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Gritstone Joins Collaborative Cancer Research Initiative; Shares Rise 4% Pre-Bell	23-08-07
Moderna/Merck inicia estudio de fase final de combinación de vacunas contra el cáncer de piel	23-07-26
Moderna/Merck begins late-stage study of skin cancer vaccine combination	23-07-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Other languages

Filters